What is the current state of the market when it comes to immunotherapies?
Take us under the hood and in the boardroom in terms of leadership around this partnership and building a parallel track of revenue growth and clinical research. I know you've done a lot of trials and things like that. So in your leadership role, how does it work in terms of reaching out to prospective companies that would partner and building that business connection?
The first thing is to focus on the science because Alexis, the science is what cures people. For the really first time in history in the last three years, the death rate is starting to come down for cancer and that's just based on good science. And so everything that we do has to be based on great science.
There's a lot of hope in that kind of collaboration. Building on the Turnstone example, when you have that, how do you build on that kind of business partnership to attract others, like-minded companies or institutions, research institutions? Does that have a sort of additive effect of finding other partners?Absolutely. What we want to do is focus on the great science. We don't want to ever lower that bar. We have huge bandwidth.